To assess the capability of perfusion MRI to differentiate between necrosis and tumor recurrence in patients showing radiological progression of cerebral metastases treated with stereotactic radiosurgery (SRS). From 2004 to 2006 dynamic susceptibility-weighted contrast-enhanced perfusion MRI scans were performed on patients with cerebral metastasis showing radiological progression after SRS during follow-up. Several perfusion MRI characteristics were examined: a subjective visual score of the relative cerebral blood volume (rCBV) map and quantitative rCBV measurements of the contrast-enhanced areas of maximal perfusion. For a total of 34 lesions in 31 patients a perfusion MRI was performed. Diagnoses were based on histology, definite radiological decrease or a combination of radiological and clinical follow-up. The diagnosis of tumor recurrence was obtained in 20 of 34 lesions, and tumor necrosis in 14 of 34. Regression analyses for all measures proved statistically significant (χ2 = 11.6–21.6, P < 0.001–0.0001). Visual inspection of the rCBV map yielded a sensitivity and specificity of 70.0 respectively 92.9%. The optimal cutoff point for maximal tumor rCBV relative to white matter was 2.00 (improving the sensibility to 85.0%) and 1.85 relative to grey matter (GM), improving the specificity to 100%, with a corresponding sensitivity of 70.0%. Perfusion MRI seems to be a useful tool in the differentiation of necrosis and tumor recurrence after SRS. For the patients displaying a rCBV-GM greater than 1.85, the diagnosis of necrosis was excluded. Salvage treatment can be initiated for these patients in an attempt to prolong survival.
Introduction
Cerebral metastases affect 20–30% of all cancer patients and form the second most common cerebral neoplasm in adults [1, 2]. Stereotactic radiosurgery (SRS), either as a single modality or in combination with whole brain radiotherapy (WBRT), is an established treatment option for patients with a limited number of brain metastases, increasing the mean overall survival rate from 3 to 6 months after WBRT to approximately 8–12 months [1, 15, 22, 33, 34]. Radiation-induced changes on follow-up MRI studies have been reported in up to 22% of patients, and are frequently impossible to differentiate from local tumor progression [18, 35, 37, 39, 44, 50, 51]. In case of local tumor recurrence, surgical resection or repeat radiosurgery can be considered as salvage options for selected patients who are in good clinical condition and have stable or absent extracranial disease, underscoring the clinical relevance of this diagnostic dilemma.
Histological verification of recurrence constitutes the gold standard, but this requires a resection of the lesion rather than biopsy for reasons of spatial heterogeneity, i.e., regions of viable tumor and necrosis may co-exist after SRS. Several non-invasive techniques, including SPECT, MR spectroscopy (HMRS) and PET, have been used to differentiate between radionecrosis and tumor progression [11, 17, 43, 47]. For FDG-PET, sensitivities between 65 and 86% (with MRI co-registration) and for HMRS and SPECT sensitivities and specificities around 85%-90% are reported, favoring SPECT [5, 11, 18, 19]. Besides the financial and labor-intensive aspects of these techniques, one of the major disadvantages is that the relatively low resolution might prevent (early) detection of recurrence in these heterogenous lesions [12]. Recent MRI techniques with higher spatial resolution have been suggested to yield better results [48, 52].
Anzeige
Dynamic susceptibility-weighted contrast-enhanced (DSC) or perfusion MRI is capable of quantifying microvessel density (vascularity) and permeability of brain tissue by assessment of the relative cerebral blood volume (rCBV) [3, 8, 10, 25, 27, 38, 46] and has been used for grading, histological differentiation and assessment of prognosis in glioma patients [6, 7, 16, 24, 29, 32, 54]. The literature on the use of DSC MRI for brain metastases is limited and mainly focuses on predicting treatment response [23, 48, 53].
The goal of this study is to evaluate the capability of perfusion MRI for differentiating between radiation-induced tumor necrosis and tumor progression in patients with radiosurgically treated cerebral metastases with progressive lesions during follow-up in the presence of salvage options.
Methods and materials
Patient population
At the VU University Medical Center Amsterdam, patients with one to three brain metastases have been treated with SRS as a single modality since 2002. The SRS dose varied between 18 and 21 Gy prescribed at the 80% isodose, depending on the size of the treated lesion. The SRS-alone treatment option was combined with standardized MRI follow-up at 3-month intervals in order to allow for timely salvage therapy, when indicated. Those patients demonstrating a progression in volume of the treated lesion during follow-up and who were candidates for salvage therapy in the form of surgery or repeat SRS based on their general condition and extracranial tumor status routinely underwent a perfusion MRI to differentiate between radiation-induced tumor necrosis and tumor recurrence.
A total of 31 such patients harboring 34 treated lesions form the basis of this study. Relevant patient and treatment characteristics are shown in Table 1. The majority of patients (19/31) had metastases from lung cancer. The pre-radiosurgery metastasis volume ranged from 0.6 to 31.6 cm3 (mean 8.0 cm3). The mean volume after radiosurgery (prior to progression, i.e., the minimum volume measured during follow-up) was 3.2 cm3 (range 0.1–10.7 cm3). The corresponding volume at the time of progression (and of the perfusion MRI) was 7.2 cm3 (range 0.2–25.3 cm3). The median SRS dose was 21 Gy, prescribed at the 80% isodose. Four patients had received WBRT prior to SRS with a total dose of 20 Gy in five fractions of 4 Gy.
Table 1
Patient characteristics and perfusion measures
Patient
Metastasis
Initial prior
TTP
PPS
OS
Clinical
rCBV
rCBV map
Sex
Age
Prim. tumor
Vol (cc)
Dose
Therapy
Diagnosis
WM
GM
Diagnosis
1
M
54
Lung
19.8
24
None
10
6.5
16.8
Necrosis
1.57
0.62
Necrosis
2
M
68
Lung
10.5
21
NSR + RTH
4
1
5.2
Progression
2.31
0.99
Progression
3
M
57
Lung
1.1
21
BPY + RTH
8.5
16.5
25.2
Progression*
4.69
2.66
Progression
4
F
66
Lung
7.1
24
None
6
2
8.2
Necrosis
0.94
0.48
Necrosis
5
M
43
Lung
5.8
18
NSR
3
17.5
20.6
Progression*
6.72
5.16
Progression
6
F
47
Lung
3.0
21
None
17
20
36.6
Necrosisa
1.50
0.78
Non concl.
7a
M
44
Lung
13.6
18
None
12
12
23.9
Progression
4.15
1.99
Progression
7b
M
44
Lung
2.6
18
None
12
12
23.9
Necrosisa
3.87
1.85
Non concl.
8
M
43
Lung
3.8
21
None
7.5
6
13.7
Necrosis
0.94
0.47
Non concl.
9
F
56
Lung
18.9
24
RTH
11
9
20.0
Progression
4.73
3.49
Progression
10
F
58
Lung
5.8
18
None
9
20
29.2
Necrosisa
1.64
0.60
Necrosis
11
F
72
Lung
9.2
21
None
3.5
1.5
4.9
Progression
0.97
0.55
Necrosis
12
F
47
Lung
6.4
18
None
7.5
20.5
28.0
Necrosisa
3.09
0.59
Necrosis
13
M
45
Lung
13.0
24
None
7
4.5
11.9
Necrosis
1.98
1.09
Necrosis
14
F
72
Lung
1.7
15
None
7.5
11.5
19.3
Necrosis
3.71
1.47
Necrosis
15
M
58
Lung
8.4
18
RTH
6
1.5
7.6
Progression
2.04
1.95
Necrosis
16
F
57
Lung
0.9
21
None
7.5
3
10.3
Progression*
2.80
0.78
Necrosis
17
F
62
Lung
10.7
18
None
6.5
7
13.5
Progression
3.90
2.29
Progression
18
F
41
Lung
12.7
24
None
4
6.5
10.5
Progression*
4.67
2.22
Progression
19
M
70
Lung
3.9
18
None
8.5
5
13.6
Progression
2.58
1.45
Non concl.
20
F
51
Mamma
9.1
18
None
9.5
7
16.8
Progression
4.19
2.32
Progression
21
F
36
Mamma
10.6
18
NSR
11.5
12.5
24.2
Necrosis
2.31
1.33
Necrosis
22
F
51
Mamma
8.1
18
None
7
22
28.8
Progression*
13.69
5.74
Progression
23
F
36
Mamma
1.3
15
None
7
28
35.5
Necrosisa
1.24
0.92
Non concl.
24
F
46
Mamma
0.6
21
NSR
15
24
38.6
Progression
6.22
2.67
Progression
25a
F
54
Ovary
4.1
18
None
7.5
4
11.8
Progression
2.40
1.86
Progression
25b
F
54
Ovary
1.2
18
None
7.5
4
11.8
Progression*
5.86
4.54
Progression
25c
F
54
Ovary
15.4
18
None
7.5
4
11.8
Progression
1.23
0.95
Necrosis
26
M
53
Melanoma
20.8
24
None
9
5.5
14.4
Progression
7.84
4.66
Progression
27
F
62
Melanoma
3.3
21
None
12
1
12.9
Progression
0.75
0.31
Necrosis
28
F
60
Renal cell
3.8
21
None
7.5
3
10.6
Necrosis
1.56
1.17
Progression
29
M
59
Renal cell
3.2
21
None
7
7.5
14.7
Progression
4.21
2.77
Progression
30
M
49
Bladder
31.6
24
None
9.5
3.5
13.2
Necrosis
0.55
0.55
Non concl.
31
F
56
Colon
0.9
21
None
8
16
23.9
Necrosis
0.47
0.29
Necrosis
The first columns show the most important patient characteristics; the last three show the different perfusion parameters. Age is in years; dose is radiation dose in Grays at the 80% isodose center; survival times are in months. NSR neurosurgical resection, BPY biopsy, RTH radiotherapy, TTP time to (radiological) progression, OS overall survival time, PPS survival time after radiological progression. rCBV relative cerebral blood volume, WM white matter, GM grey matter, non concl non-conclusive. *Diagnosis based on histology, adiagnosis based on radiological decrease at follow-up
Anzeige
Clinical outcome
Although histopathological verification is the gold standard in differentiating between tumor recurrence or radiation-induced tumor necrosis, this was available in only a small subgroup. In addition, some patients showed a substantial regression of lesion volume on subsequent follow-up MRI scans without additional treatment, making a diagnosis of tumor necrosis highly likely, and of tumor recurrence very unlikely. In all other patients, the clinical diagnosis was assessed subjectively using radiological and clinical follow-up data. A rapidly deteriorating neurological condition, short survival time due to neurological progression, or ongoing progression in subsequent MRI scans was considered indicative of tumor progression. All clinical diagnoses were defined retrospectively by the treating physician (FL), who was blinded to the perfusion MRI findings.
MRI
Imaging was performed on a 1.5-T MRI scanner (Siemens Sonata, Siemens Medical Systems, Erlangen, Germany). After a localizing sagittal T1-weighted image, non-enhanced axial T1-weighted spin echo [repetition time/echo time (TR/TE) 600/12 ms] and axial T2-weighted (3,680/85) images were obtained. Post-contrast axial and sagittal (MPR) T1-weighted imaging was performed after the acquisition of the DSC MRI data.
DSC MRI scans were acquired with a gradient-echo echoplanar imaging (GE-EPI) technique during the first pass of a standard dose (0.1 mmol/kg) bolus of gadolinium contrast (Magnevist; Berlex Laboratories). Imaging parameters were: TR/TE 1,440/47; slice thickness 5 mm, interslice gap 1.5 mm, field of view 230–230 mm, matrix 128–128 leading to pixel size 0.9–0.9 mm (after interpolation), flip angle 90°, and signal bandwidth, 1,345 Hz/pixel. The injection rate of the contrast was 5 ml/s. A total of 50 images were acquired at 1.44-s intervals with the bolus typically arriving between the 10th and 15th image. The post-processing of the DSC MRI data were performed on a Leonardo VD10B Syngo OEM installation (Siemens AG).
DSC measurements
The DSC MRI scans were scored based on both subjective and objective evaluations of the rCBV maps by an experienced neuroradiologist (E.S.), who was blinded with respect to the clinical information and outcome.
Subjective scoring of the rCBV maps
The rCBV map was evaluated alongside the post-contrast structural MRI series. A subjective diagnosis of “tumor progression” was based on the presence of nodular highly vascularized areas within the contrast-enhanced lesion, irrespective of areas indicative of necrosis (Fig. 1a), relative to the contralateral hemisphere. Alternatively, a diagnosis of “tumor necrosis” was made in case of a clear absence of perfusion (black hole), in the absence of any nodular highly vascularized area (Fig. 1b). When neither a high perfusion area nor a clear perfusion absence could be determined, the rCBV map was scored as “non-conclusive.”
Fig. 1
rCBV maps and T1-weighted scans after gadolinium administration. Patient A shows a clear high rCBV at the site of the contrast-enhanced lesion (Fig. 1a, arrow), suggestive of tumor recurrence. The lesion was resected, and the histological diagnosis was tumor recurrence. Patient B displays a perfusion absence (Fig. 1b, “black spot,” arrow), suggestive of necrosis, at the lesion site as indicated by the post-contrast scan. This was confirmed by clinical and radiological follow-up. For the last patient (C) the rCBV map was judged “inconclusive,” since no clear high CBV nor a clear absence thereof (between arrows) was present at the site of enhancement. The clinical diagnosis based on continued clinical and radiological follow-up was necrosis
×
rCBV measurements
The procedure used to calculate rCBV from DSC MRI data is based on standard algorithms. The principles of calculating rCBV from signal intensity curves during the first pass of a bolus contrast agent have been described extensively by others [14, 20]. Since spatial heterogeneity is a possible confounding factor in recurrent lesions, rCBVs were calculated for the highest perfusion fraction, irrespective of whether that area was judged as being actually high relative to contralateral white or grey matter, in concordance with previous reports [24, 26, 55]. In addition, as irradiated tumor rCBVs typically lie between white matter and grey matter values [17], a mean grey matter CBV, calculated from three regions Of interest (ROIs) spread over the contralateral cortex (one frontal, one temporal and one occipital) after exclusion of large vessels to minimize the chances of partial volume of white matter voxels [28] was used as a reference region in addition to a contralateral white matter reference region (semioval center). Thus, two quantitative parameters were calculated: rCBV-WM and rCBV-GM.
In 6 of the 34 lesions (18%), a histological diagnosis was obtained (1 post-mortem), and all showed viable tumor on pathological examination. Five lesions (15%) showed subsequent spontaneous radiological regression without treatment, indicative of tumor necrosis. Thus, an objective outcome parameter could be obtained for 11 lesions (35%). For the remaining 23 lesions, the clinical diagnosis was assigned as tumor recurrence in 14 lesions and tumor necrosis in 9 lesions, based retrospectively on radiological follow-up and clinical course. In total, 20 lesions (59%) were assigned to the recurrence group and 14 lesions (41%) to the tumor necrosis group (see Fig. 2).
Fig. 2
Distribution of diagnoses across lesions. In total, 20 lesions were considered to be tumor progression (6 with a histologically confirmed diagnosis and 14 with a clinical diagnosis) and 14 to be radiation necrosis (5 regressing lesions on further follow-up and 9 based on clinical diagnoses)
×
The mean time to radiological progression, i.e., the interval between SRS and lesion enlargement on follow-up MRI scans, was not significantly different between the two groups: 9.2 ± 2.8 months for the tumor necrosis group and 7.8 ± 3.0 months for the tumor progression group (P = 0.21). Although the mean survival calculated from the time of suspected recurrence (time of perfusion MRI) was longer for the patients scored as having tumor necrosis (13.4 ± 8.6 months) than for the tumor recurrence patients (8.4 ± 7.1 months), this difference did not reach statistical significance (P = 0.08), see Fig. 3 (left Kaplan–Meier curve). However, 8 of the 20 patients with tumor recurrence received adjuvant treatment (5 patients underwent neurosurgical resection, and 3 patients received radiotherapy) and had a mean survival from time of radiological progression of 12.8 months, against a mean survival of 5.4 months in the remaining patients, thereby prolonging the survival of the total recurrence group. The mean overall survival for the entire cohort (all 31 patients) is remarkably long: 18.8 months from the moment of initial SRS.
Fig. 3
Kaplan–Meier survival curves. The curve shows no significant survival between the tumor progression (dotted line) and radiation necrosis group (straight line); survival in months, after radiological enlargement of the stereotactically irradiated lesion
×
Subjective scoring of the rCBV map
Fifteen of the 34 lesions were classified as tumor recurrence (Fig. 1a), and 13 lesions were diagnosed as radiation necrosis (Fig. 1b). This left six lesions for which the rCBV map was considered non-conclusive (Fig. 1c) (Table 1). Logistic regression analysis was performed to calculate how well the rCBV map diagnosis in itself is capable of predicting actual clinical tumor recurrence, and this showed a sensitivity and specificity of 70.0 and 92.9%, respectively (χ2 = 15.99; df = 2; P < 0.001; R2 0.506), and positive (PPV) and negative predictive values (NPV) of 93.3% and 68.4%, respectively. Of the six dubious lesions (either because of a faint ring around the lesion on the rCBV map or the absence of a clear necrotic/very low perfusion area) for which no diagnosis could be obtained by subjective scoring of the rCBV map, five were judged radiation effects, and just one was considered tumor progression, based on clinical outcome.
Anzeige
Quantitative rCBV measures
The mean rCBV of the recurrence group was significantly larger than that of the tumor necrosis group for both rCBV-WM and rCBV-GM (mean differences of −2.5 respectively −1.6, see Table 2). Logistic regression analysis yielded statistically significant models for both rCBV measures, favoring rCBVmax-GM, with a fairly good sensitivity and specificity ranging from 71.4 to 80.0% (see Table 3). ROC curves, plotted for both measures (Fig. 4 and Table 3) to demarcate the optimal cutoff point and corresponding rCBV value, yielded cutoff points of 2.00 and 1.85. This resulted in a sensitivity of 85% and corresponding specificity of 71.4% for rCBVmax-WM and a 100% specificity with corresponding sensitivity of 70% for rCBVmax-GM (Table 2). In other words, all lesions displaying a maximal rCBV higher than 1.85 relative to grey matter could be identified as tumor recurrence.
Table 2
rCBV means and group differences
Variable
Necrosis (n = 14)
Progression (n = 20)
t
P-value
95% CI
rCBV-high-WM
1.8123
4.2982
−3.459
0.002
(−3.96 −1.01)
rCBV-high-GM
0.8723
2.4672
−4.336
<0.001
(−2.36 −0.84)
Table 3
Results of logistic regression analysis (univariate)
Variable
χ2*
Sign.
Nagelkerke R2
Sensitivity (%)
Specificity (%)
Accuracy (%)
All lesions
rCBV map
15.992
<0.001
0.506
70.0
92.9
79.4
rCBV-high-WM
11.897
0.001
0.398
80.0
71.4
76.5
rCBV-high-GM
15.697
<0.001
0.498
75.0
78.6
76.5
rCBVmax-GM > 1.85
21.635
<0.001
0.634
70.0
100.0
82.4
rCBVmax-WM > 2.00
11.574
0.001
0.389
85.0
71.4
79.4
Certain diagnosis
rCBV map
11.339
0.003
0.86
83.3
100.0
90.9
rCBV-high-WM
8.604
0.003
0.725
83.3
80.0
81.8
rCBV-high-GM
7.526
0.006
0.663
83.3
80.0
81.8
rCBVmax-GM > 1.85
9.751
0.002
0.786
83.3
100.0
90.9
rCBVmax-WM > 2.00
6.161
0.013
0.573
100.0
60.0
81.8
Results are shown for several parameters. First the rCBV map diagnosis and the quantitative measures rCBV-high-WM and -GM, representing the highest perfusion fraction relative to white and grey matter, were separately entered. Next, the procedure was repeated for the high rCBV measures at their most discriminative cutoffs (1.85 and 2.0 relative to contralateral grey matter and white matter, respectively), according to the ROC curve analysis (see Fig. 4), thereby dichotomizing the groups. *df = 2 for rCBV map and df = 1 for all other variables
Fig. 4
ROC curves. The figure displays the ROC curves for rCBV-high-WM (straight line) and -GM (dotted line), with areas under curves of 0.827 and 0.839, respectively. The most discriminative cutoff point for rCBV-high-WM (*) is 2.01 with a sensitivity of 85.0% and specificity of 71.4%. For rCBV-high-GM, this point (**) corresponds to a cutoff of 1.85 with a sensitivity of 70.0% and specificity of 100%
×
When the subgroup of patients with a histologically confirmed diagnosis or with spontaneous tumor regression on follow-up imaging was evaluated, analysis of the perfusion parameters demonstrated even better results with accuracies ranging from 81.8 to 90.9% (Table 3). Using a cutoff value of 2.0 for the rCBVmax_WM, a sensitivity of 100% was reached, and likewise a specificity of 100% when a rCBVmax_GM higher than 1.85 was chosen. Despite these remarkable results and even distribution, the total number of patients is considered too small to draw any firm conclusions.
Discussion
Enlargement of metastatic lesions after SRS, suggesting either tumor recurrence or necrosis and affecting 20–28% of all treated lesions, constitutes a clinically relevant diagnostic dilemma in patients in good functional condition and with stable extracranial disease. The long mean overall survival in this study of 18.8 months after SRS illustrates this fact. In order to prevent unnecessary neurosurgical interventions or expensive, labour-intensive and often inconclusive imaging techniques, the efficacy of perfusion MRI to differentiate between tumor necrosis and recurrence was evaluated. In our series, the detection of a nodular fractional high perfusion area on the rCBV map (within the contrast-enhanced lesion) or a maximum rCBV higher than 1.85 relative to grey matter was indicative of tumor recurrence, with a specificity of 100% and sensitivity of 70.0%. In a small subgroup of patients with “certain” diagnoses, these results even improved (i.e., the sensitivity), which points to a possible underestimation of its recurrence detection potential.
Current imaging modalities
Traditionally, PET, SPECT and (lately) H-MR spectroscopy have been used to evaluate the ‘tumor recurrence—radiation-induced necrosis’ dilemma. In general (FDG)PET is probably the least sensitive, although better results are reported for high grade gliomas than for metastases, for which sensitivities between 65 and 80% are reported, with an improvement to 86% with MRI co-registration [5, 11, 13]. The use of 11C-methionine-tracers seems to improve these results somewhat [45, 49]. The results for HMRS and SPECT are variable [4, 13, 30, 36, 40‐42, 45], with most papers reporting the superiority of SPECT (sensitivity and specificity around 90–100%), but again mainly in high grade gliomas. The results drop to sensitivities between 85 and 91% when metastases only are considered, unfortunately usually without histological diagnosis [19, 43].
Anzeige
In particular, the pitfall of frequent false-positive findings that are obtained with these techniques remains a matter of concern [39], as this may results in unnecessary interventions with associated morbidity or mortality. The advantage of the method we used is the high specificity, excluding false-positive results, and the better resolution than on Spect, HMRS and Pfalse
ET, since 90% of the resected SRS-treated recurrent metastases are known to demonstrate a mixture of tumor proliferation and necrosis [48].
Metastasis and perfusion MRI: rationale and literature
The blood volume in tumor progression (represented by the rCBV) is increased as a consequence of a combination of intravascular and extravascular components: neocapillary formation, dilatation of existing vasculature and high permeability of metastatic tumor vessels [3, 8‐10, 25]. Although the contrast enhancement of radiation effects is also a consequence of increased vascular permeability, there is a clear difference between the vascular dynamics of this increase compared to tumor progression. The transport of blood (contrast) into necrotic areas is a consequence of slow permeability limited by the diffusion distance (not measured by rCBV), whereas the fast permeability seen in (metastatic) viable tissue is determined by vessel permeability, which is partially responsible for the increased blood volume [31]. Areas with radiation-induced necrosis, on the contrary, do not show an increased intravascular blood volume. Hence, contrast enhancement, which is an indicator of integrity of the blood-brain-barrier, is not equivalent to the perfusion abnormalities measured by the rCBV, which measures vascularity and might therefore differentiate between necrosis and progression [20, 25].
Previous reports on SRS-treated metastases have demonstrated that temporal changes in perfusion MRI measurements are useful for differentiating radiological responders from non-responders [23, 53]. However, in these studies no differentiation was made between tumor necrosis and recurrence. Others have differentiated between these two diagnoses using perfusion MRI; however, this was only for (high grade) gliomas [17, 47]. Truong et al. used perfusion MRI in the evaluation of progressive metastases after SRS and found a reasonable positive predictive value of 80% in a subgroup of patients (15/38). Although they obtained a histological diagnosis in all patients, in contrast to our study, their measurements were not quantified, and no true-negative lesions were reported, despite two false-negative lesions [48]. Our results are in agreement with the results of Koichi et al. [21], who found the same cutoff value of 2.0 relative to WM for differentiating necrosis from tumor recurrence after SRS.
Perfusion MRI sensitivity
A substantial portion of the progressive metastases possibly remain undetected given the calculated sensitivity. Part of this underestimation might be due to an incorrect clinical diagnosis since a considerably higher sensitivity and larger mean difference between both groups were found in the “certain diagnosis” analysis. Alternatively, since the rCBV values of treated enhancing tumor lie between the rCBV of white and grey matter, as stated by Henry et al., the assessment of cortical lesions is problematic, and relatively high rCBVs are needed for a clear diagnosis of tumor progression, thereby challenging overall sensitivity [17]. The regional cerebral blood volume (rCBV) of white matter (especially when edema is present) is low compared to the rCBV of grey matter, and the rCBV of treated lesions in this study often showed intermediate values. Any (small) increase in rCBV of treated lesions, e.g., due to radiation-induced or inflammatory reactions of surrounding tissues, will have a relatively higher impact on the ratio rCBV-lesion/rCBV-WM than on the rCBV-lesion/rCBV-GM. This could lead to a false-positive labeling of lesions as ‘progression’ based on rCBV-WM.
Anzeige
Secondly, lesions are often located on the junction of grey and white matter. Since the rCBV map has a lower resolution than the conventional MRI, controversy might arise whether the area of enhanced perfusion is due to a progression of the metastasis in the white matter, or surrounding grey matter. When the rCBV is higher than the grey matter, the odds are that the high perfusion indeed indicates progressive disease. On the other hand, one could speculate that initial tumor recurrence is possibly independent of increasing vasculature, and therefore, a relatively early perfusion scan might miss the correct diagnosis. In this respect, others have found serial perfusion MRI more accurate in the evaluation of radiated metastases [23, 53].
Limitations
Several limitations of the present study need to be addressed. First, and most importantly, in only a small subgroup of the patients (18%) a definite histological diagnosis was established. This is however inherent to the clinical dilemma, since the majority of patients present with an asymptomatic radiological enlargement during routine follow-up. For these patients with a high probability of radiation effects, the risks of possible complications of a resection or biopsy was deemed to outbalance the benefits of a confirmative tissue diagnosis. The volumetric decrease during further follow-up in a significant proportion of the patients together with the fact that no cases of radiation necrosis were demonstrated among the operated patients seems to justify this wait-and-scan policy.
The authors of this study felt that judgment of the clinical course until death, or at least 5 months after performing the perfusion scan, combined with frequent radiological evaluation justified the assignment to a diagnosis group in the absence of histological confirmation. Our results obtained through a clinical diagnosis have led to a possible underestimation of the capacity of perfusion MRI to differentiate between both entities, since better results were achieved for the “certain diagnosis” subgroup.
Secondly, our conclusions are based on a rather limited number of patients. The group is however homogenous, with a clinically relevant dilemma, and all data were gathered through a consistent protocol for all patients. We are continuing to perform perfusion MRI scans in patients with enlarging lesions during follow-up after radiosurgery for brain metastases, and will update the findings in due course. Finally, since perfusion MRI was done on indication (i.e., after progressive contrast enhancement), not all perfusion scans were achieved at the same time point after SRS. Theoretically this poses the problem of introducing early transient radiation effects, which occur slightly earlier (within 3 months) than tumor recurrence or radiation necrosis [18]. However, all perfusion scans in this study were performed at least 3 months after SRS (mean 8.4 months), thereby excluding possible contamination with transient radiation effects.
Conclusion
In conclusion, DSC MRI appears to be a useful instrument to differentiate between tumor recurrence and radiation necrosis after stereotactically irradiated cerebral metastases. Based on our data, a cutoff rCBV value higher than 1.85 relative to gray matter can be used to diagnose tumor progression, as no patient with radionecrosis had values exceeding this value. However, a value lower than 1.85 cannot be used for diagnosing radionecrosis, since some patients with (eventual) progressive disease displayed lower values. To further improve the sensitivity of this modality, future research is needed to elucidate a potential benefit of repeated perfusion MRI measurements possibly in conjunction with other imaging modalities.
Conflict of interest notification
No actual or potential conflict of interest exists.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
